Neal Rosen: Publications

Share
Print
Share
Print

Yao, Z., Gao, Y., Su, W., Yaeger, R., Tao, J., Na, N., Zhang, Y., Zhang, C., Rymar, A., Tao, A., Timaul, N. M., Mcgriskin, R., Outmezguine, N. A., Zhao, H., Chang, Q., Qeriqi, B., Barbacid, M., de Stanchina, E., Hyman, D. M., Bollag, G., … Rosen, N. (2019). RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nature medicine, 25(2), 284–291. https://doi.org/10.1038/s41591-018-0274-5

Gao, Y., Chang, M. T., McKay, D., Na, N., Zhou, B., Yaeger, R., Torres, N. M., Muniz, K., Drosten, M., Barbacid, M., Caponigro, G., Stuart, D., Moebitz, H., Solit, D. B., Abdel-Wahab, O., Taylor, B. S., Yao, Z., & Rosen, N. (2018). Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer discovery, 8(5), 648–661. https://doi.org/10.1158/2159-8290.CD-17-1452

Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M., You, D., Viale, A., Kemeny, N., Segal, N. H., Stadler, Z. K., Varghese, A. M., Kundra, R., Gao, J., Syed, A., Hyman, D. M., … Schultz, N. (2018). Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer cell, 33(1), 125–136.e3. https://doi.org/10.1016/j.ccell.2017.12.004

Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., Baselga, J., de Stanchina, E., Saltz, L., Berger, M. F., Solit, D. B., & Rosen, N. (2017). Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer research, 77(23), 6513–6523. https://doi.org/10.1158/0008-5472.CAN-17-0768

Yao, Z., Yaeger, R., Rodrik-Outmezguine, V. S., Tao, A., Torres, N. M., Chang, M. T., Drosten, M., Zhao, H., Cecchi, F., Hembrough, T., Michels, J., Baumert, H., Miles, L., Campbell, N. M., de Stanchina, E., Solit, D. B., Barbacid, M., Taylor, B. S., & Rosen, N. (2017). Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature, 548(7666), 234–238. https://doi.org/10.1038/nature23291.

Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., Barratt, D. G., Cosulich, S., Klinowska, T., Rosen, N., & Shokat, K. M. (2016). Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature, 534(7606), 272–276. https://doi.org/10.1038/nature17963

Lito, P., Solomon, M., Li, L. S., Hansen, R., & Rosen, N. (2016). Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science (New York, N.Y.), 351(6273), 604–608. https://doi.org/10.1126/science.aad6204

Yao, Z., Torres, N. M., Tao, A., Gao, Y., Luo, L., Li, Q., de Stanchina, E., Abdel-Wahab, O., Solit, D. B., Poulikakos, P. I., & Rosen, N. (2015). BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer cell, 28(3), 370–383. https://doi.org/10.1016/j.ccell.2015.08.001

Schwartz, S., Wongvipat, J., Trigwell, C. B., Hancox, U., Carver, B. S., Rodrik-Outmezguine, V., Will, M., Yellen, P., de Stanchina, E., Baselga, J., Scher, H. I., Barry, S. T., Sawyers, C. L., Chandarlapaty, S., & Rosen, N. (2015). Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer cell, 27(1), 109–122. https://doi.org/10.1016/j.ccell.2014.11.008

Lito, P., Rosen, N., & Solit, D. B. (2013). Tumor adaptation and resistance to RAF inhibitors. Nature medicine, 19(11), 1401–1409. https://doi.org/10.1038/nm.3392